Skog S - Search Results

1

Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay.

Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E, Zhou J, Skog S. Chen ZH, et al. Among authors: skog s. Sensors (Basel). 2011;11(12):11064-80. doi: 10.3390/s111211064. Epub 2011 Nov 28. Sensors (Basel). 2011. PMID: 22247653 Free PMC article.

2

Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours.

Chen Z, Zhou H, Li S, He E, Hu J, Zhou J, Skog S. Chen Z, et al. Among authors: skog s. Anticancer Res. 2008 Nov-Dec;28(6B):3897-907. Anticancer Res. 2008. PMID: 19192647 Free article.

3

Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.

Luo P, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S. Luo P, et al. Among authors: skog s. Eur J Cancer Prev. 2009 Jun;18(3):220-4. doi: 10.1097/CEJ.0b013e328329d817. Eur J Cancer Prev. 2009. PMID: 19282758

4

The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells.

Luo P, Wang N, He E, Eriksson S, Zhou J, Hu G, Zhang J, Skog S. Luo P, et al. Among authors: skog s. Pathol Oncol Res. 2010 Jun;16(2):277-83. doi: 10.1007/s12253-009-9222-5. Epub 2009 Dec 3. Pathol Oncol Res. 2010. PMID: 19957115 Free article.

5

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Pan ZL, et al. Among authors: skog s. J Cancer Res Clin Oncol. 2010 Aug;136(8):1193-9. doi: 10.1007/s00432-010-0769-z. Epub 2010 Feb 7. J Cancer Res Clin Oncol. 2010. PMID: 20140744

6

Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Chen Y, Ying M, Chen Y, Hu M, Lin Y, Chen D, Li X, Zhang M, Yun X, Zhou J, He E, Skog S. Chen Y, et al. Among authors: skog s. Int J Clin Oncol. 2010 Aug;15(4):359-68. doi: 10.1007/s10147-010-0067-4. Epub 2010 Apr 1. Int J Clin Oncol. 2010. PMID: 20354751

7

Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas.

Li Z, Wang Y, He J, Ma J, Zhao L, Chen H, Li N, Zhou J, He E, Skog S. Li Z, et al. Among authors: skog s. Eur J Cancer Prev. 2010 Jul;19(4):313-8. doi: 10.1097/CEJ.0b013e32833ad320. Eur J Cancer Prev. 2010. PMID: 20479645

8

Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.

Li Z, Wang Y, Ma J, He J, Zhou J, He E, Skog S. Li Z, et al. Among authors: skog s. Anticancer Res. 2010 Apr;30(4):1295-9. Anticancer Res. 2010. PMID: 20530443

9

Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.

He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL, Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T, Skog S. He E, et al. Among authors: skog s. Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):352-8. doi: 10.1080/15257771003738535. Nucleosides Nucleotides Nucleic Acids. 2010. PMID: 20544519

10

Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management.

Guan H, Sun Y, Zan Q, Xu M, Li Y, Zhou J, He E, Eriksson S, Wen W, Skog S. Guan H, et al. Among authors: skog s. Mol Med Rep. 2009 Nov-Dec;2(6):923-9. doi: 10.3892/mmr_00000193. Mol Med Rep. 2009. PMID: 21475922

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

132 results

Search Page